TLR9 recognition of mtDNA DAMPs leading to pro-fibrotic signaling through upregulation, activation, and release of TGF-β has been previously described in other fibrotic disorders such as systemic sclerosis and in a model of prostate cancer [34, 35]. This evidence concerns the gene TLR9 and prostate carcinoma.